NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free NPCE Stock Alerts $7.09 -0.44 (-5.84%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$6.75▼$7.8850-Day Range$7.09▼$15.3352-Week Range$3.80▼$18.15Volume105,720 shsAverage Volume107,966 shsMarket Capitalization$203.98 millionP/E RatioN/ADividend YieldN/APrice Target$15.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get NeuroPace alerts: Email Address NeuroPace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside121.0% Upside$15.67 Price TargetShort InterestHealthy0.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.53Based on 4 Articles This WeekInsider TradingSelling Shares$7.58 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.14) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.35 out of 5 starsMedical Sector222nd out of 931 stocksSurgical & Medical Instruments Industry32nd out of 101 stocks 3.4 Analyst's Opinion Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuroPace has only been the subject of 3 research reports in the past 90 days.Read more about NeuroPace's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.91% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently increased by 39.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NPCE. Previous Next 3.6 News and Social Media Coverage News SentimentNeuroPace has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for NeuroPace this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for NPCE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,583,250.00 in company stock.Percentage Held by Insiders22.20% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeuroPace's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($1.14) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 8.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NeuroPace's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About NeuroPace Stock (NASDAQ:NPCE)NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More NPCE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NPCE Stock News HeadlinesMay 4, 2024 | insidertrades.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 4,674 Shares of StockMay 27 at 8:52 AM | finance.yahoo.comNeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 47% stake, while 24% is held by institutionsMay 18, 2024 | americanbankingnews.comContrasting Tactile Systems Technology (NASDAQ:TCMD) and NeuroPace (NASDAQ:NPCE)May 14, 2024 | finance.yahoo.comNeuroPace to Participate in Two Healthcare Conferences in MayMay 13, 2024 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing ChallengesMay 10, 2024 | markets.businessinsider.comNeuroPace’s Strong Q1 Performance and Promising Growth Prospects Affirm Buy RatingMay 9, 2024 | finanznachrichten.deNeuroPace, Inc: NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...May 8, 2024 | msn.comNeuroPace GAAP EPS of -$0.32May 8, 2024 | globenewswire.comNeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comNeuroPace is about to announce its earnings — here's what Wall Street expectsApril 20, 2024 | investing.comOrbiMed Advisors sells shares in NeuroPace worth over $238,000April 17, 2024 | globenewswire.comNeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024April 10, 2024 | fool.comNeuroPace (NASDAQ: NPCE)April 4, 2024 | msn.com'Biggest mistake' bond investors may make ahead of Fed rate cutsMarch 27, 2024 | globenewswire.comNeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceMarch 13, 2024 | markets.businessinsider.comThe Latest Analyst Ratings For NeuroPaceMarch 7, 2024 | markets.businessinsider.comNeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth DriversMarch 7, 2024 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comNeuroPace Full Year 2023 Earnings: EPS Beats ExpectationsMarch 7, 2024 | seekingalpha.comNeuroPace, Inc. (NPCE) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | benzinga.comRecap: NeuroPace Q4 EarningsMarch 6, 2024 | msn.comNeuroPace GAAP EPS of -$0.23March 6, 2024 | markets.businessinsider.comNeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending ConcernsSee More Headlines Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/28/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NPCE CUSIPN/A CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees171Year FoundedN/APrice Target and Rating Average Stock Price Target$15.67 High Stock Price Target$22.00 Low Stock Price Target$9.00 Potential Upside/Downside+121.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,960,000.00 Net Margins-45.61% Pretax Margin-45.61% Return on Equity-173.62% Return on Assets-30.89% Debt Debt-to-Equity Ratio4.05 Current Ratio6.43 Quick Ratio5.56 Sales & Book Value Annual Sales$65.42 million Price / Sales3.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book8.97Miscellaneous Outstanding Shares28,770,000Free Float22,382,000Market Cap$203.98 million OptionableOptionable Beta2.06 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Joel D. Becker (Age 56)CEO, President & Director Comp: $762kMs. Rebecca L. Kuhn (Age 63)CFO, VP of Finance & Administration, Corporate Secretary and Assistant Secretary Comp: $614.91kDr. Martha J. Morrell (Age 67)Chief Medical Officer Comp: $728.68kMs. Leah AkinActing General CounselMs. Kelley NicholasVice President of SalesMs. Irene Thomas (Age 55)Vice President of Human Resources More ExecutivesKey CompetitorsDelcath SystemsNASDAQ:DCTHAngioDynamicsNASDAQ:ANGOUtah Medical ProductsNASDAQ:UTMDAVITA MedicalNASDAQ:RCELNyxoahNASDAQ:NYXHView All CompetitorsInsiders & InstitutionsKent Lake Capital LLCSold 27,317 shares on 5/16/2024Ownership: 2.237%Hillsdale Investment Management Inc.Bought 11,750 shares on 5/11/2024Ownership: 0.041%Vanguard Group Inc.Bought 75,512 shares on 5/10/2024Ownership: 1.701%Acadian Asset Management LLCBought 47,215 shares on 5/10/2024Ownership: 0.164%Orbimed Advisors LlcSold 4,674 sharesTotal: $65,576.22 ($14.03/share)View All Insider TransactionsView All Institutional Transactions NPCE Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroPace stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NPCE shares. View NPCE analyst ratings or view top-rated stocks. What is NeuroPace's stock price target for 2024? 7 Wall Street research analysts have issued twelve-month price objectives for NeuroPace's stock. Their NPCE share price targets range from $9.00 to $22.00. On average, they expect the company's stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price. View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts. How have NPCE shares performed in 2024? NeuroPace's stock was trading at $10.31 at the beginning of 2024. Since then, NPCE stock has decreased by 31.2% and is now trading at $7.09. View the best growth stocks for 2024 here. Are investors shorting NeuroPace? NeuroPace saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 125,500 shares, an increase of 39.8% from the April 30th total of 89,800 shares. Based on an average daily volume of 118,100 shares, the short-interest ratio is presently 1.1 days. Approximately 0.9% of the shares of the company are sold short. View NeuroPace's Short Interest. When is NeuroPace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our NPCE earnings forecast. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32). The company had revenue of $18.12 million for the quarter, compared to analyst estimates of $18.12 million. NeuroPace had a negative net margin of 45.61% and a negative trailing twelve-month return on equity of 173.62%. What guidance has NeuroPace issued on next quarter's earnings? NeuroPace issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $73.0 million-$77.0 million, compared to the consensus revenue estimate of $75.2 million. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. Who are NeuroPace's major shareholders? NeuroPace's stock is owned by many different retail and institutional investors. Top institutional shareholders include Kent Lake Capital LLC (2.24%), Vanguard Group Inc. (1.70%), Acadian Asset Management LLC (0.16%) and Hillsdale Investment Management Inc. (0.04%). Insiders that own company stock include Accelmed Partners Ii LP, Irina Ridley, Ltd Kck, Martha Morrell and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NPCE) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
